Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed.

1. Escalated lymphodepletion followed by donor lymphocyte infusion can induce a graft-versus-host response without overwhelming toxicity.Bone marrow transplantation · 2012
   Trial
2. Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials.Leukemia · 2010
   Trial
3. Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation.Bone marrow transplantation · 2016
   Article
4. New strategies of DLI in the management of relapse of hematological malignancies after allogeneic hematopoietic SCT.Bone marrow transplantation · 2016
   Review
5. Minimal residual disease as a predictive factor for relapse after allogeneic hematopoietic stem cell transplant in adult patients with acute myeloid leukemia in first and second complete remission.Cancers · 2012
   Article
6. Interferon-α in acute myeloid leukemia: an old drug revisited.Leukemia · 2011
   Review
7. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.Cancer · 2010
   Article
8. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2010
   Article
9. Relapse after allogeneic hematopoietic cell therapy.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2010
   Review
10. Gemtuzumab ozogamicin-induced long-term remission in a woman with acute myelomonocytic leukemia and bone marrow relapse following allogeneic transplantation.International journal of hematology · 2009
    Article
11. Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant.Bone marrow transplantation · 2008
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as